FI930846A - HOMOCONJUGERADE IMMUNOGLOBULINER - Google Patents
HOMOCONJUGERADE IMMUNOGLOBULINER Download PDFInfo
- Publication number
- FI930846A FI930846A FI930846A FI930846A FI930846A FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A
- Authority
- FI
- Finland
- Prior art keywords
- immunoglobuliner
- homoconjugerade
- homoconjugerade immunoglobuliner
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57572590A | 1990-08-31 | 1990-08-31 | |
US74866291A | 1991-08-26 | 1991-08-26 | |
PCT/US1991/006195 WO1992004053A1 (en) | 1990-08-31 | 1991-08-29 | Homoconjugated immunoglobulins |
Publications (2)
Publication Number | Publication Date |
---|---|
FI930846A0 FI930846A0 (en) | 1993-02-25 |
FI930846A true FI930846A (en) | 1993-04-05 |
Family
ID=27076774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI930846A FI930846A (en) | 1990-08-31 | 1993-02-25 | HOMOCONJUGERADE IMMUNOGLOBULINER |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0547137A4 (en) |
JP (1) | JPH06500780A (en) |
KR (1) | KR930702029A (en) |
AU (1) | AU8506991A (en) |
CA (1) | CA2090317A1 (en) |
FI (1) | FI930846A (en) |
IE (1) | IE913071A1 (en) |
IL (1) | IL99363A0 (en) |
NZ (1) | NZ239617A (en) |
PT (1) | PT98840A (en) |
WO (1) | WO1992004053A1 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2281300A (en) * | 1993-08-26 | 1995-03-01 | Merck & Co Inc | Anti-HIV antibody oligomer |
US6368596B1 (en) * | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101027427B1 (en) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | Fc VARIANTS WITH INCREASED BINDING TO FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
JP4860703B2 (en) | 2005-10-06 | 2012-01-25 | ゼンコー・インコーポレイテッド | Optimized anti-CD30 antibody |
ES2402591T3 (en) | 2006-08-14 | 2013-05-07 | Xencor Inc. | Optimized antibodies that target CD19 |
EP2064240A2 (en) | 2006-09-18 | 2009-06-03 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
AU2008345242B2 (en) | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
SG175004A1 (en) | 2009-04-02 | 2011-11-28 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
EP2417159A1 (en) | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-3/anti-c-met antibodies |
JP5616428B2 (en) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | Trivalent bispecific antibody |
KR20110124368A (en) | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | Bispecific anti-erbb-2/anti-c-met antibodies |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
TWI426920B (en) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-vegf/anti-ang-2 antibodies |
AR080793A1 (en) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | BISPECIFIC ANTIBODIES |
JP5758004B2 (en) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Bispecific antibodies comprising Fv fragments stabilized by disulfides |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
BR112014019579A2 (en) | 2012-02-10 | 2019-10-15 | Genentech, Inc | SINGLE CHAIN ANTIBODY, POLYNUCLEOTIDE, VECTOR, HOST CELL, METHOD OF PRODUCTION OF A SINGLE CHAIN ANTIBODY, HETEROMULTYMER AND METHOD OF PRODUCTION |
SG11201406238UA (en) | 2012-04-05 | 2014-10-30 | Hoffmann La Roche | Bispecific antibodies against human tweak and human il17 and uses thereof |
BR112014028368A2 (en) | 2012-06-27 | 2017-11-14 | Hoffmann La Roche | method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation |
ES2597228T3 (en) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedure for the selection and production of objectification entities, such as targets, highly selective and multi-specific, customized, which contain at least two different binding entities, and use of these |
EP2869837B1 (en) | 2012-07-04 | 2016-09-14 | F. Hoffmann-La Roche AG | Anti-theophylline antibodies and methods of use |
EP3339328A1 (en) | 2012-07-04 | 2018-06-27 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
BR112014029403A2 (en) | 2012-07-04 | 2018-10-09 | F. Hoffmann-La Roche Ag | conjugates, antibody and pharmaceutical formulation |
CN104341504B (en) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | Bispecific antibody |
PT3083680T (en) | 2013-12-20 | 2020-03-17 | Hoffmann La Roche | Humanized anti-tau(ps422) antibodies and methods of use |
CN105873615B (en) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
BR112016013849A2 (en) | 2014-01-03 | 2017-10-10 | Hoffmann La Roche | bispecific antihapten / blood-brain barrier receptor conjugates, their uses, and pharmaceutical formulation |
JP6521464B2 (en) | 2014-01-03 | 2019-05-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Covalently linked polypeptide toxin-antibody conjugates |
AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
CN107810196B (en) | 2015-06-24 | 2021-11-05 | 豪夫迈·罗氏有限公司 | Humanized anti-Tau (pS422) antibodies and methods of use |
CA3081560A1 (en) * | 2017-11-07 | 2019-05-16 | Hubit Genomix, Inc. | Method for primary prevention of allergic disorders during infancy through ige-class-specific immunosuppression |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422653D0 (en) * | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
AU648056B2 (en) * | 1989-11-07 | 1994-04-14 | Bristol-Myers Squibb Company | Oligomeric immunoglobulins |
-
1991
- 1991-08-29 CA CA002090317A patent/CA2090317A1/en not_active Abandoned
- 1991-08-29 AU AU85069/91A patent/AU8506991A/en not_active Abandoned
- 1991-08-29 KR KR1019930700605A patent/KR930702029A/en not_active Application Discontinuation
- 1991-08-29 WO PCT/US1991/006195 patent/WO1992004053A1/en not_active Application Discontinuation
- 1991-08-29 JP JP3515144A patent/JPH06500780A/en active Pending
- 1991-08-29 EP EP19910916502 patent/EP0547137A4/en not_active Ceased
- 1991-08-30 IE IE307191A patent/IE913071A1/en unknown
- 1991-08-30 PT PT98840A patent/PT98840A/en not_active Application Discontinuation
- 1991-08-30 NZ NZ239617A patent/NZ239617A/en unknown
- 1991-09-01 IL IL99363A patent/IL99363A0/en unknown
-
1993
- 1993-02-25 FI FI930846A patent/FI930846A/en unknown
Also Published As
Publication number | Publication date |
---|---|
FI930846A0 (en) | 1993-02-25 |
KR930702029A (en) | 1993-09-08 |
AU8506991A (en) | 1992-03-30 |
PT98840A (en) | 1992-07-31 |
JPH06500780A (en) | 1994-01-27 |
NZ239617A (en) | 1993-11-25 |
EP0547137A4 (en) | 1993-12-08 |
IE913071A1 (en) | 1992-03-11 |
WO1992004053A1 (en) | 1992-03-19 |
IL99363A0 (en) | 1992-08-18 |
EP0547137A1 (en) | 1993-06-23 |
CA2090317A1 (en) | 1992-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO924798D0 (en) | HAARFORMINGSSJAMPOER | |
ATA150090A (en) | HOERGERAET | |
FI930846A (en) | HOMOCONJUGERADE IMMUNOGLOBULINER | |
FI925594A0 (en) | FOTOGRAFISERIE | |
FI930878A (en) | A-SUBSTITUERADE TRYPTOFAN-DIPEPTOIDDERIVAT | |
FI925980A (en) | BISHETEROCYCLISKA FOERENINGAR | |
ATA210290A (en) | LOTPILLE | |
FI931157A0 (en) | 5-TRIFLUORACYLAMINO-2-ARYLOXATZOLER | |
FI924890A0 (en) | HYBRIDCELLRECEPTOR | |
FI931749A (en) | NYTT ISOMERISATIONSENZYM | |
ATA80690A (en) | ALPINSCHI | |
FI84789C (en) | FAESTSYSTEM OCH -ANORDNING | |
ATA200090A (en) | PIANINO | |
ATA237490A (en) | RINNENSTEIN | |
ATA209290A (en) | DIARAEHMCHEN | |
FI924460A0 (en) | HMG-COA-REDUCTIVE INHIBITORER | |
NO178511C (en) | Presstörke | |
FI930896A0 (en) | ENSILAGETILLSATS | |
BR7001930U (en) | TERRARIO | |
BR7000495U (en) | LIFE-BREAKER | |
BR7002566U (en) | ALUVIONAR MINERATOR | |
BR7002265U (en) | TRUMB | |
BR7001933U (en) | PULALASTIC | |
BR7002609U (en) | CAMELOMOVEL | |
BR7001859U (en) | PROTELETRON |